Literature DB >> 18409031

Functional genomics of hTERT gene in leukemic myelopoiesis.

Deepak Kaul1, A Gautam, S Varma, A Ahlawat.   

Abstract

Keeping in view the fact that a single acquired genetic abnormality "Bcr-Abl chimeric gene" accompanied by elevated telomerase activity has been widely recognized to be responsible for the leukemic myelopoiesis observed in chronic myeloid leukemia (CML), the present study was addressed to understand as to how selective and specific knock-down of human telomerase reverse transcriptase (hTERT) gene within mononuclear cells derived from untreated CML subjects could influence the apoptotic, genotypic (such as Bcr-Abl; C-myc; Bcl-2; IL-6; GMCSF; IL-3; and acetylated H(3) and H(4)), and phenotypic (such as CD34 and CD89) characteristics of these cells. Based upon these results, we propose that hTERT gene-based drug design may be useful in the treatment of leukemic myelopoiesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18409031     DOI: 10.1007/s11010-008-9760-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  18 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells.

Authors:  I Sakai; A S Kraft
Journal:  J Biol Chem       Date:  1997-05-09       Impact factor: 5.157

3.  Defective RNA-mediated c-myc gene silencing pathway in Burkitt's lymphoma.

Authors:  Deepak Kaul; Kavleen Sikand
Journal:  Biochem Biophys Res Commun       Date:  2004-01-16       Impact factor: 3.575

4.  Cytokines as suppressors of apoptosis.

Authors:  J Lotem; L Sachs
Journal:  Apoptosis       Date:  1999-06       Impact factor: 4.677

Review 5.  Receptor-Ck and leukemogenesis.

Authors:  D Kaul
Journal:  Leuk Res       Date:  1998-05       Impact factor: 3.156

Review 6.  The biology of interleukin-6.

Authors:  T Kishimoto
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

7.  Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.

Authors:  M Engelhardt; K Mackenzie; P Drullinsky; R T Silver; M A Moore
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

Review 8.  Telomeres and telomerase in hematologic neoplasia.

Authors:  Junko H Ohyashiki; Goro Sashida; Tetsuzo Tauchi; Kazuma Ohyashiki
Journal:  Oncogene       Date:  2002-01-21       Impact factor: 9.867

Review 9.  Telomere biology of human hematopoietic stem cells.

Authors:  Ngaire Elwood
Journal:  Cancer Control       Date:  2004 Mar-Apr       Impact factor: 3.302

10.  Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells.

Authors:  T Kinoshita; T Yokota; K Arai; A Miyajima
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

View more
  1 in total

1.  Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.

Authors:  Yutaka Kawano; Haesook T Kim; Ken-Ichi Matsuoka; Gregory Bascug; Sean McDonough; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2011-09-07       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.